Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.
| dc.rights.license | open | en_US |
| dc.contributor.author | VERGÈS, Bruno | |
| dc.contributor.author | ABOYANS, Victor | |
| dc.contributor.author | ANGOULVANT, Denis | |
| dc.contributor.author | BOUTOUYRIE, Pierre | |
| dc.contributor.author | CARIOU, Bertrand | |
| dc.contributor.author | HYAFIL, Fabien | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | MOHAMMEDI, Kamel | |
| dc.contributor.author | AMARENCO, Pierre | |
| dc.date.accessioned | 2023-03-03T11:04:17Z | |
| dc.date.available | 2023-03-03T11:04:17Z | |
| dc.date.issued | 2022-11-15 | |
| dc.identifier.issn | 1475-2840 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/172154 | |
| dc.description.abstractEn | Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential mechanisms of stroke protection by GLP-1RAs. GLP-1RAs exert multiple anti-atherosclerotic effects contributing to stroke prevention such as enhanced plaque stability, reduced vascular smooth muscle proliferation, increased nitric oxide, and improved endothelial function. GLP-1RAs also lower the risk of stroke by reducing traditional stroke risk factors including hyperglycemia, hypertension, and dyslipidemia. Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood-brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion. Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Animals | |
| dc.subject.en | Humans | |
| dc.subject.en | Glucagon-Like Peptide-1 Receptor | |
| dc.subject.en | Hypoglycemic Agents | |
| dc.subject.en | Diabetes Mellitus | |
| dc.subject.en | Type 2 | |
| dc.subject.en | Stroke | |
| dc.subject.en | Hyperglycemia | |
| dc.title.en | Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. | |
| dc.title.alternative | Cardiovasc Diabetol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s12933-022-01686-3 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Médecine humaine et pathologie | en_US |
| dc.identifier.pubmed | 36380358 | en_US |
| bordeaux.journal | Cardiovascular Diabetology | en_US |
| bordeaux.page | 242 | en_US |
| bordeaux.volume | 21 | en_US |
| bordeaux.hal.laboratories | Biologie des maladies cardiovasculaires (BMC) - UMR 1034 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04013171 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-03-03T11:04:20Z | |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | CC BY | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cardiovascular%20Diabetology&rft.date=2022-11-15&rft.volume=21&rft.issue=1&rft.spage=242&rft.epage=242&rft.eissn=1475-2840&rft.issn=1475-2840&rft.au=VERG%C3%88S,%20Bruno&ABOYANS,%20Victor&ANGOULVANT,%20Denis&BOUTOUYRIE,%20Pierre&CARIOU,%20Bertrand&rft.genre=article |
